Efficacy and safety of once‐weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once‐daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open‐label, phase III, non‐inferiority study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 10, 2015-10 ,pp. : 994-1002

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of once‐weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once‐daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open‐label, phase III, non‐inferiority study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 1462-8902, Iss. 10, 2015-10 ,pp. : 994-1002

John Wiley & Sons Inc

Access to resources Recommend Favorite

Health-Related Quality-of-Life Outcomes in Patients Treated with Push-Pull OROS Hydromorphone versus Extended-Release Oxycodone for Chronic Hip or Knee Osteoarthritis Pain: A Randomized, Open-Label, Parallel-Group, Multicenter Study

By Gajria Kavita  

The Patient: Patient-Centered Outcomes Research, Vol. 1, Iss. 3, 2008-01 ,pp. : 223-238

Adis International

Access to resources Recommend Favorite

Open-label study of the safety and effectiveness of long-term therapy with extended-release tramadol in the management of chronic nonmalignant pain

By Pascual Maria Luz G.   Fleming Rosa Rosanna B.   Gana Theophilus J.   Vorsanger Gary J.  

Current Medical Research and Opinion, Vol. 23, Iss. 10, 2007-10 ,pp. : 2531-2542

Informa Healthcare

Access to resources Recommend Favorite

Comparative Effects of Morning vs Evening Dosing of Extended‐Release Hydromorphone on Sleep Physiology in Patients with Low Back Pain: A Pilot Study

By  

PAIN MEDICINE, Vol. 16, Iss. 3, 2015-03 ,pp. : 460-471

John Wiley & Sons Inc

Access to resources Recommend Favorite